SG10201608684QA - Injectable formulation - Google Patents

Injectable formulation

Info

Publication number
SG10201608684QA
SG10201608684QA SG10201608684QA SG10201608684QA SG10201608684QA SG 10201608684Q A SG10201608684Q A SG 10201608684QA SG 10201608684Q A SG10201608684Q A SG 10201608684QA SG 10201608684Q A SG10201608684Q A SG 10201608684QA SG 10201608684Q A SG10201608684Q A SG 10201608684QA
Authority
SG
Singapore
Prior art keywords
injectable formulation
injectable
formulation
Prior art date
Application number
SG10201608684QA
Other languages
English (en)
Inventor
Tetsuya Sato
Takuya Minowa
Yusuke Hoshika
Hidekazu Toyofuku
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49483139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201608684Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG10201608684QA publication Critical patent/SG10201608684QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201608684QA 2012-04-23 2013-04-23 Injectable formulation SG10201608684QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636932P 2012-04-23 2012-04-23
US201361791896P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10201608684QA true SG10201608684QA (en) 2016-12-29

Family

ID=49483139

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201406775UA SG11201406775UA (en) 2012-04-23 2013-04-23 Injectable formulation
SG10201608684QA SG10201608684QA (en) 2012-04-23 2013-04-23 Injectable formulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201406775UA SG11201406775UA (en) 2012-04-23 2013-04-23 Injectable formulation

Country Status (32)

Country Link
US (5) US20150086632A1 (ru)
EP (1) EP2868318B2 (ru)
JP (1) JP6249944B2 (ru)
KR (1) KR102168263B1 (ru)
CN (4) CN107536802A (ru)
AR (1) AR090775A1 (ru)
AU (1) AU2013253518B2 (ru)
BR (1) BR112014026398B1 (ru)
CA (1) CA2871398C (ru)
CO (1) CO7151499A2 (ru)
CY (1) CY1123195T1 (ru)
DK (1) DK2868318T4 (ru)
EA (1) EA026124B1 (ru)
ES (1) ES2727454T5 (ru)
HK (1) HK1205678A1 (ru)
HR (1) HRP20190841T4 (ru)
HU (1) HUE043686T2 (ru)
IL (1) IL235211A0 (ru)
IN (1) IN2014DN08870A (ru)
JO (1) JO3524B1 (ru)
LT (1) LT2868318T (ru)
MX (1) MX361722B (ru)
MY (1) MY169099A (ru)
NZ (1) NZ630255A (ru)
PH (1) PH12014502366A1 (ru)
PL (1) PL2868318T5 (ru)
PT (1) PT2868318T (ru)
SG (2) SG11201406775UA (ru)
SI (1) SI2868318T2 (ru)
TW (1) TWI641395B (ru)
UA (1) UA118084C2 (ru)
WO (1) WO2013161830A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
WO2017106641A1 (en) * 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
WO2018033483A1 (en) * 2016-08-16 2018-02-22 H E X A L Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
WO2018141886A1 (en) * 2017-02-02 2018-08-09 Hexal Aktiengesellschaft Crystalline brexpiprazole
WO2020196814A1 (en) * 2019-03-28 2020-10-01 Otsuka Pharmaceutical Co., Ltd. Benzoazepine compound-containing freeze-dried composition
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
CA3225183A1 (en) 2021-09-07 2023-03-16 Ming Li Long-acting brexpiprazole preparation for injection and preparation method therefor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051281A1 (fr) 1997-05-14 1998-11-19 Senju Pharmaceutical Co., Ltd. Preparations a base de suspensions aqueuses possedant d'excellentes proprietes de redispersion
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
AU2001278779A1 (en) 2000-08-25 2002-03-04 Senju Pharmaceutical Co. Ltd. Aqueous suspension preparations
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
MXPA06004489A (es) * 2003-10-23 2006-06-20 Otsuka Pharma Co Ltd Formulacion y metodo de aripiprazol inyectable esteril de liberacion controlada.
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20070148100A1 (en) * 2005-09-15 2007-06-28 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
TWI415629B (zh) * 2006-10-26 2013-11-21 Otsuka Pharma Co Ltd 含有瑞巴匹特之水性醫藥懸浮物及其製造方法
NZ582415A (en) * 2007-07-31 2012-05-25 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
ES2471122T3 (es) * 2008-03-11 2014-06-25 Alcon Research, Ltd. Suspensiones de acet�nido de triamcinolona altamente floculadas y de baja viscosidad para inyección intrav�trea
KR101748890B1 (ko) * 2008-11-19 2017-06-19 메리얼 인코포레이티드 세프티오퍼 및 케토프로펜 또는 세프티오퍼 및 벤질 알코올을 포함하는 제형
JP5575269B2 (ja) * 2010-08-24 2014-08-20 大塚製薬株式会社 カルボスチリル誘導体並びにシリコーンオイル及び/又はシリコーンオイル誘導体を含有する懸濁液及びケーキ組成物
KR101936968B1 (ko) * 2010-10-18 2019-01-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 주사용 서방형 제제
PL3156056T3 (pl) * 2011-03-18 2024-04-29 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne zawierające estry sorbitanu
JP2012232958A (ja) 2011-05-09 2012-11-29 Otsuka Pharmaceut Co Ltd 注射製剤
JP6333802B2 (ja) * 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن

Also Published As

Publication number Publication date
US20180092910A1 (en) 2018-04-05
CN111888329A (zh) 2020-11-06
MX2014012734A (es) 2015-04-10
UA118084C2 (uk) 2018-11-26
TWI641395B (zh) 2018-11-21
CA2871398A1 (en) 2013-10-31
CY1123195T1 (el) 2021-10-29
BR112014026398B1 (pt) 2022-11-29
AU2013253518A1 (en) 2014-11-06
CN104363912A (zh) 2015-02-18
HK1205678A1 (en) 2015-12-24
SI2868318T1 (sl) 2019-06-28
CN107536802A (zh) 2018-01-05
KR20150003336A (ko) 2015-01-08
PH12014502366B1 (en) 2015-01-12
US20220305007A1 (en) 2022-09-29
US20200163960A1 (en) 2020-05-28
BR112014026398A2 (pt) 2017-06-27
EA026124B1 (ru) 2017-03-31
NZ630255A (en) 2016-05-27
SG11201406775UA (en) 2014-12-30
US20150086632A1 (en) 2015-03-26
MX361722B (es) 2018-12-14
DK2868318T3 (da) 2019-06-03
IL235211A0 (en) 2014-12-31
EP2868318A1 (en) 2015-05-06
EP2868318B1 (en) 2019-03-06
US20240277702A1 (en) 2024-08-22
JP6249944B2 (ja) 2017-12-20
US10624889B2 (en) 2020-04-21
AU2013253518B2 (en) 2017-10-05
EA201491937A1 (ru) 2015-03-31
DK2868318T4 (da) 2022-03-28
PL2868318T5 (pl) 2022-06-20
JO3524B1 (ar) 2020-07-05
WO2013161830A1 (ja) 2013-10-31
PT2868318T (pt) 2019-06-07
SI2868318T2 (sl) 2022-04-29
JPWO2013161830A1 (ja) 2015-12-24
LT2868318T (lt) 2019-07-25
TW201406401A (zh) 2014-02-16
CO7151499A2 (es) 2014-12-29
EP2868318A4 (en) 2015-12-09
ES2727454T3 (es) 2019-10-16
PL2868318T3 (pl) 2019-09-30
HRP20190841T4 (hr) 2022-03-04
KR102168263B1 (ko) 2020-10-21
AR090775A1 (es) 2014-12-03
CA2871398C (en) 2021-04-27
MY169099A (en) 2019-02-18
HUE043686T2 (hu) 2019-09-30
IN2014DN08870A (ru) 2015-05-22
EP2868318B2 (en) 2022-01-26
ES2727454T5 (es) 2022-05-13
PH12014502366A1 (en) 2015-01-12
CN110638752A (zh) 2020-01-03
HRP20190841T1 (hr) 2019-07-26

Similar Documents

Publication Publication Date Title
HK1257028A1 (zh) 可注射製劑
HRP20190841T1 (hr) Injektabilna formulacija
HK1203193A1 (en) Aprepitant injectable formulations
HK1205877A1 (en) Injectable ibuprofen formulation
GB201200707D0 (en) Composition
HK1204551A1 (en) Injectable compositions
HK1202445A1 (en) New formulation
ZA201306000B (en) Stable formulation
EP2878295A4 (en) COMPOSITION
EP2887953A4 (en) IMPROVED INJECTABLE FORMULATION OF DAPTOMYCIN
GB201206035D0 (en) Composition
EP2837670A4 (en) COMPOSITION CONTAINING FLUOROBIPHENYL
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
EP2910538A4 (en) AGENT COMPOSITION GENERATING GAS
GB201211247D0 (en) Improved formulation
GB201205861D0 (en) Composition
GB201202695D0 (en) Composition